972 - Imipenem-Cilastatin-Relebactam (I/R) Pharmacokinetics (PK) in Critically Ill Patients Supported on Extracorporeal Membrane Oxygenation (ECMO)

Presenting Author(s)

• 

  Andrew J. Fratoni, PharmD

  Associate Director, Clinical and Laboratory Studies
  Hartford Hospital
  Hartford, CT, United States

  Slides

Co-Author(s)

• AK

  Abigail Kois, PharmD

  Hartford Hospital
  Chevy Chase, Maryland, United States
• JG

  Jason A. Gluck, DO, FACC

  Director, Mechanical Circulatory Support Program and Director, Emergency Cardiac Care
  Hartford Hospital
  Hartford, Connecticut, United States
• DN

  David P. Nicolau, PharmD

  Director
  Hartford Hospital
  Hartford, Connecticut, United States
• 

  Joseph L. Kuti, PharmD

  Associate director
  Hartford Hospital
  Hartford, Connecticut, United States